Literature DB >> 27321472

APOE ε4 carriers may undergo synaptic damage conferring risk of Alzheimer's disease.

Xiaoyan Sun1, Chuanhui Dong2, Bonnie Levin2, Elizabeth Crocco3, David Loewenstein3, Henrik Zetterberg4, Kaj Blennow5, Clinton B Wright2.   

Abstract

INTRODUCTION: Pathogenesis of Alzheimer's disease (AD) in apolipoprotein E ε4 (APOE ε4) carriers remains unclear. We hypothesize that APOE isoforms have differential effects on synaptic function.
METHODS: We compared levels of CSF neurogranin (Ng) between APOE ε4 carriers and noncarriers in 399 subjects with normal cognition, mild cognitive impairment (MCI), and AD. We examined associations between Ng levels and age, education, gender, CSF-Aβ42, and tau protein.
RESULTS: Neurogranin levels were significantly higher in APOE ε4 carriers compared to APOE ε4 noncarriers with MCI. Levels of Ng between the APOE ε4 carriers and APOE ε4 noncarriers with AD did not differ. Ng levels were correlated with MMSE and levels of tau and Aβ42. DISCUSSION: Significantly higher CSF Ng levels in APOE ε4 carriers with MCI may reflect synaptic injury underlying early cognitive impairment. Neurogranin may be an early biomarker of AD and important for disease diagnosis and timing of intervention in APOE ε4 carriers.
Copyright © 2016 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  APOE; APOE ε4; Alzheimer's disease; Mild cognitive impairment; Neurogranin; Synaptic function

Mesh:

Substances:

Year:  2016        PMID: 27321472      PMCID: PMC5742562          DOI: 10.1016/j.jalz.2016.05.003

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  33 in total

1.  Dendritic translocation of RC3/neurogranin mRNA in normal aging, Alzheimer disease and fronto-temporal dementia.

Authors:  J W Chang; E Schumacher; P M Coulter; H V Vinters; J B Watson
Journal:  J Neuropathol Exp Neurol       Date:  1997-10       Impact factor: 3.685

2.  Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism.

Authors:  Eric M Reiman; Kewei Chen; Gene E Alexander; Richard J Caselli; Daniel Bandy; David Osborne; Ann M Saunders; John Hardy
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-02       Impact factor: 11.205

Review 3.  Amyloid-dependent and amyloid-independent stages of Alzheimer disease.

Authors:  Bradley T Hyman
Journal:  Arch Neurol       Date:  2011-04-11

4.  Drebrin, a dendritic spine protein, is manifold decreased in brains of patients with Alzheimer's disease and Down syndrome.

Authors:  Ki Shuk Shim; Gert Lubec
Journal:  Neurosci Lett       Date:  2002-05-24       Impact factor: 3.046

5.  Neurogranin null mutant mice display performance deficits on spatial learning tasks with anxiety related components.

Authors:  T Miyakawa; E Yared; J H Pak; F L Huang; K P Huang; J N Crawley
Journal:  Hippocampus       Date:  2001       Impact factor: 3.899

6.  Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease.

Authors:  Hlin Kvartsberg; Flora H Duits; Martin Ingelsson; Niels Andreasen; Annika Öhrfelt; Kerstin Andersson; Gunnar Brinkmalm; Lars Lannfelt; Lennart Minthon; Oskar Hansson; Ulf Andreasson; Charlotte E Teunissen; Philip Scheltens; Wiesje M Van der Flier; Henrik Zetterberg; Erik Portelius; Kaj Blennow
Journal:  Alzheimers Dement       Date:  2014-12-19       Impact factor: 21.566

7.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.

Authors:  Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski
Journal:  Ann Neurol       Date:  2009-04       Impact factor: 10.422

Review 8.  Apolipoprotein e sets the stage: response to injury triggers neuropathology.

Authors:  Robert W Mahley; Yadong Huang
Journal:  Neuron       Date:  2012-12-06       Impact factor: 17.173

9.  Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium.

Authors:  L A Farrer; L A Cupples; J L Haines; B Hyman; W A Kukull; R Mayeux; R H Myers; M A Pericak-Vance; N Risch; C M van Duijn
Journal:  JAMA       Date:  1997 Oct 22-29       Impact factor: 56.272

Review 10.  Oligomeric Aβ-induced synaptic dysfunction in Alzheimer's disease.

Authors:  Shichun Tu; Shu-ichi Okamoto; Stuart A Lipton; Huaxi Xu
Journal:  Mol Neurodegener       Date:  2014-11-14       Impact factor: 14.195

View more
  13 in total

1.  Alzheimer disease: Elevated neurogranin levels reveal early synaptic damage in APOE* ɛ4 carriers.

Authors: 
Journal:  Nat Rev Neurol       Date:  2016-07-01       Impact factor: 42.937

2.  CSF VEGF Was Positively Associated with Neurogranin Independent of β-Amyloid Pathology.

Authors:  Yangping Huang; Jun Wang; Bihong Zhu; Pan Fu
Journal:  Neuropsychiatr Dis Treat       Date:  2020-07-22       Impact factor: 2.570

3.  Neurogranin as a predictor of memory and executive function decline in MCI patients.

Authors:  Alison Headley; Andres De Leon-Benedetti; Chuanhui Dong; Bonnie Levin; David Loewenstein; Christian Camargo; Tatjana Rundek; Henrik Zetterberg; Kaj Blennow; Clinton B Wright; Xiaoyan Sun
Journal:  Neurology       Date:  2018-02-02       Impact factor: 9.910

4.  Intrahippocampal injection of a lentiviral vector expressing neurogranin enhances cognitive function in 5XFAD mice.

Authors:  Seong Gak Jeon; Moonkyung Kang; Yeon-Soo Kim; Dong-Hyun Kim; Dong Woo Nam; Eun Ji Song; Inhee Mook-Jung; Minho Moon
Journal:  Exp Mol Med       Date:  2018-03-23       Impact factor: 8.718

5.  Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology.

Authors:  Erik Portelius; Bob Olsson; Kina Höglund; Nicholas C Cullen; Hlin Kvartsberg; Ulf Andreasson; Henrik Zetterberg; Åsa Sandelius; Leslie M Shaw; Virginia M Y Lee; David J Irwin; Murray Grossman; Daniel Weintraub; Alice Chen-Plotkin; David A Wolk; Leo McCluskey; Lauren Elman; Jennifer McBride; Jon B Toledo; John Q Trojanowski; Kaj Blennow
Journal:  Acta Neuropathol       Date:  2018-04-26       Impact factor: 17.088

6.  Association of Clusterin Levels in Cerebrospinal Fluid with Synaptic Degeneration Across the Alzheimer's Disease Continuum.

Authors:  Jun Wang; Xin Zhang; Bihong Zhu; Pan Fu
Journal:  Neuropsychiatr Dis Treat       Date:  2020-01-20       Impact factor: 2.570

Review 7.  Neurogranin and VILIP-1 as Molecular Indicators of Neurodegeneration in Alzheimer's Disease: A Systematic Review and Meta-Analysis.

Authors:  Maciej Dulewicz; Agnieszka Kulczyńska-Przybik; Barbara Mroczko
Journal:  Int J Mol Sci       Date:  2020-11-06       Impact factor: 5.923

8.  Neurogranin as a cognitive biomarker in cerebrospinal fluid and blood exosomes for Alzheimer's disease and mild cognitive impairment.

Authors:  Weilin Liu; Huawei Lin; Xiaojun He; Lewen Chen; Yaling Dai; Weiwei Jia; Xiehua Xue; Jing Tao; Lidian Chen
Journal:  Transl Psychiatry       Date:  2020-04-29       Impact factor: 7.989

9.  Association between plasma exosome neurogranin and brain structure in patients with Alzheimer's disease: a protocol study.

Authors:  MengFei He; Li Sun; Wenhui Cao; Changhao Yin; Wenqiang Sun; Ping Liu; Lin Tan; Zheng Xu; Weina Zhao
Journal:  BMJ Open       Date:  2020-08-16       Impact factor: 2.692

10.  Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study.

Authors:  Hana Saddiki; Aurore Fayosse; Emmanuel Cognat; Séverine Sabia; Sebastiaan Engelborghs; David Wallon; Panagiotis Alexopoulos; Kaj Blennow; Henrik Zetterberg; Lucilla Parnetti; Inga Zerr; Peter Hermann; Audrey Gabelle; Mercè Boada; Adelina Orellana; Itziar de Rojas; Matthieu Lilamand; Maria Bjerke; Christine Van Broeckhoven; Lucia Farotti; Nicola Salvadori; Janine Diehl-Schmid; Timo Grimmer; Claire Hourregue; Aline Dugravot; Gaël Nicolas; Jean-Louis Laplanche; Sylvain Lehmann; Elodie Bouaziz-Amar; Jacques Hugon; Christophe Tzourio; Archana Singh-Manoux; Claire Paquet; Julien Dumurgier
Journal:  PLoS Med       Date:  2020-08-20       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.